Should aminoglycoside antibiotics be abandoned?

American Journal of Surgery

Volumn 180, Issue 6, 2000, Pages 512-516

  English, William P ^a   Williams, Mark D ^a,b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; SULBACTAM; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTOXICATION; DRUG SENSITIVITY; GRAM NEGATIVE BACTERIUM; HUMAN; NEPHROTOXICITY; OTOTOXICITY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG UTILIZATION; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDIES;

EID: 0034469781     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(00)00539-0     Document Type: Article

References (32)

1. Age-dependent aminoglycoside nephrotoxicity
2. Aminoglycoside nephrotoxicity
3. Comparative serum bactericidal activity against Pseudomonas aeruginosa of six antipseudomonal agents
4. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials
5. Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents
6. Analysis of aminoglycosides in the treatment of gram-negative infections in surgical patients
7. Isolation of antibiotic substances from soil microorganisms with special reference to streptothricin and streptomycin
8. Aminoglycosides - 50 years on
9. Aminoglycosides: Assessing the potential for nephrotoxicity
10. A survey of prospective controlled clinical trials of gentamicin, tobramycin, amikacin and netilmicin
11. What is the cost of nephrotoxicity associated with aminoglycosides?
12. Risk factors for toxicity in elderly patients given aminoglycosides once daily
13. Aninoglycosides
14. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity
15. Pharmacodynamic characterization of nephreotoxicity associated with once-daily aminoglycoside
16. Pharmacoeconomic impact of once-daily aminoglycoside administration
17. Comparison of one-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients
18. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides
19. Empiric therapy for pneumonia in the surgical intensive care unit
20. Serum level monitoring of aminoglycoside antibiotics
21. Surface action of gentamicin on Pseudomonas aeruginosa
22. Multifactorial analyses in the diagnosis of pneumonia arising in the surgical intensive care unit
23. Role of aztreonam in the treatment of nosocomial pneumonia in the critically ill surgical patient
24. Single versus combination antimicrobial therapy for ventilator-associated pneumonia
25. Complications of nosocomial pneumonia in the surgical patient
26. Treatment of pneumonia in mechanically ventilated trauma patients
27. Superiority of aztreonam/clindamycin compared with gentamicin/clindamycin in patients with penetrating abdominal trauma
28. Waiting for microbiologic data to direct therapy against nosocomial infections in febrile surgical patents: Are outcomes worsened?
29. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa
30. Psuedomonas bacteremia. Retrospective analysis of 410 episodes
31. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients
32. The effect of aminoglycoside-induced adaptive resistance on the antibacterial activity of other antibiotics against Pseudomonas aeruginosa in vitro